View Author
cyp 3a tacrolimu genotype study transplant concentration polymorphism allele patient children cyp 3a genotype liver digoxin medication mother tacrolimus dosing requirements cyp 3a allele variant recipient effect haplotype dosing result abcb 1 genotype folic table requirement control folic acid frequency cyp 3a protein folic acid use heart pharmacol population kidney serum association protein expression variation pharmacokinetic transplantation child cl /p tacrolimus disposition motor performance rotterdam ratio score clin pharmacol disposition medication use analysis cytochrome metabolism netherland motor range periconception individual signi pharmacogenetic group blood level performance liver recipients expressor concentration /dose ratio cyp 3a expressors period relationship number cyp 3a activity 1 min sequencing center erasmu primer
10 Most Recent Publications
|
The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation
(Article)
Wildt, S.N. de Schaik, R.H.N. van Soldin, O.P. Brojeni, P.Y. Heiden, I.P. van der Parshuram, C. Nulman, I. Koren, G. |
2011-12-01
|
|
Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients
(Article)
Gijsen, V.M.G.J. Mital, S. Schaik, R.H.N. van Soldin, O.P. Heiden, I.P. van der Nulman, I. Koren, G. Wildt, S.N. de |
2011-12-01
|
|
General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect
(Article)
Obermann-Borst, S.A. Isaacs, A. Younes, Z. Schaik, R.H.N. van Heiden, I.P. van der Duyn, C.M. van Steegers-Theunissen, R.P.M. Steegers-Theunissen, R.P.M. |
2011-03-01
|
|
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib
(Article)
Deenik, W. Holt, B. van der Janssen, J.J.W.M. Chu, I.W.T. Valk, P.J.M. Ossenkoppele, G.J. Heiden, I.P. van der Sonneveld, P. Schaik, R.H.N. van Cornelissen, J.J. |
2010-12-23
|
|
Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia
(Article)
Hartman, A. Schaik, R.H.N. van Heiden, I.P. van der Broekhuis, M.J.C. Meier, M. Boer, M.L. den Pieters, R. |
2010-02-01
|
|
Maternal medication use, carriership of the ABCB1 3435C > T polymorphism and the risk of a child with cleft lip with or without cleft palate
(Article)
Bliek, B.J.B. Schaik, R.H.N. van Heiden, I.P. van der Sayed-Tabatabaei, F.A. Duijn, C.M. van Steegers, E.A.P. Steegers-Theunissen, R.P.M. |
2009-10-01
|
|
Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration
(Article)
Aarnoudse, A.-J.L.H.J. Dieleman, J.P. Visser, L.E. Arp, P.P. Heiden, I.P. van der Schaik, R.H.N. van Molokhia, M. Hofman, A. Uitterlinden, A.G. Stricker, B.H.Ch. |
2008-04-01
|
|
A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system
(Article)
Lee, S.-J. Heiden, I.P. van der Goldstein, J.A. Schaik, R.H.N. van |
2007-01-08
|
|
Sequencing: not always the "gold standard".
(Article)
Heiden, I.P. van der Werf, M.J. van der Lindemans, J. Schaik, R.H.N. van |
2004-01-01
|
|
CYP3A5 variant allele frequencies in Dutch Caucasians
(Article)
Schaik, R.H.N. van Heiden, I.P. van der Anker, J.N. van den Lindemans, J. |
2002-01-01
|
